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Original ArticleProximity Ligation Assays for In Situ
Detection of Innate Immune Activation:
Focus on In Vitro-Transcribed mRNA
Emmeline L. Blanchard,1,4 Kristin H. Loomis,1,4 Sushma M. Bhosle,1 Daryll Vanover,1 Patrick Baumhof,2
Bruno Pitard,3 Chiara Zurla,1 and Philip J. Santangelo1
1Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 313 Ferst Drive, UA Whitaker Building, Atlanta, GA
30332, USA; 2CureVac, Paul-Ehrlich-Straße 15, 72076 Tübingen, Germany; 3In-Cell-Art, 21 rue de la Noue Bras de Fer, 44200 Nantes, FranceThe characterization of innate immune activation is crucial
for vaccine and therapeutic development, including RNA-
based vaccines, a promising approach. Current measurement
methods quantify type I interferon and inﬂammatory cytokine
production, but they do not allow for the isolation of individual
pathways, do not provide kinetic activation or spatial informa-
tion within tissues, and cannot be translated into clinical
studies. Here we demonstrated the use of proximity ligation
assays (PLAs) to detect pattern recognition receptor (PRR)
activation in cells and in tissue samples. First, we validated
PLA’s sensitivity and speciﬁcity using well-characterized solu-
ble agonists. Next, we characterized PRR activation from
in vitro-transcribed (IVT) mRNAs, as well as the effect of
sequence and base modiﬁcations in vitro. Finally, we estab-
lished the measurement of PRR activation in tissue sections
via PLA upon IVT mRNA intramuscular (i.m.) injection in
mice. Overall, our results indicate that PLA is a valuable, versa-
tile, and sensitive tool to monitor PRR activation for vaccine,
adjuvant, and therapeutic screening.Received 4 July 2018; accepted 9 November 2018;
https://doi.org/10.1016/j.omtn.2018.11.002.
4These authors contributed equally to this work.
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The innate immune system is the cell’s frontline mechanism of pro-
tection against foreign pathogens.1–5 In the context of vaccine devel-
opment, innate immune response activation is desirable to develop
protective immunity.6–8 Conversely, for gene therapy, its activation
must be avoided.9–12 Thus, characterizing the activation of the innate
immune response is fundamental to understanding the efﬁcacy of
vaccines and therapeutics.
The primary controllers of the innate immune system are pattern
recognition receptors (PRRs). Among these, Toll-like receptors
(TLRs) are transmembrane receptors on the cell surface, such as
TLR4, which recognizes bacterial wall lipids, or in endosomes, such
as TLR7, which detects single-stranded RNA (ssRNA). Cytoplasmic
PRRs include retinoic acid-inducible gene I (RIG-I) or melanoma dif-
ferentiation-associated protein 5 (MDA5), which recognize short
double-stranded RNA (dsRNA) with 50 triphosphorylated (50ppp)
ends or longer dsRNA, respectively. Once activated, PRRs form52 Molecular Therapy: Nucleic Acids Vol. 14 March 2019 ª 2018 The A
This is an open access article under the CC BY license (http://creativcomplexes with adaptor molecules to begin signaling cascades that
ultimately lead to type I interferon (IFN) and cytokine induction (Fig-
ure 1A).1,13–18
ELISAs or intracellular immunoﬂuorescence is traditionally used to
assess PRR activation by measuring downstream type I IFN and
inﬂammatory cytokines synthesis.2,6,14,19,20 However, they cannot
identify speciﬁc PRR activation, since multiple pathways can lead to
similar cytokine induction and crosstalk is common.18,20 Addition-
ally, these assays prevent kinetics studies and information on cell-
to-cell variability. Lastly, most downstream measurements do not
generate spatial information of PRR activation in tissues. For vaccine
development, activation in lymph nodes is crucial to immunologic
memory.21,22 Therefore, determining if PRR activation occurs only
in proximity to the delivery site or also in draining lymph nodes is
critical. Furthermore, it is valuable to determine if activation is a result
of direct interface with the vaccine or from paracrine or endocrine
signaling. Alternatively, PRR-knockout (KO) systems can isolate sin-
gle PRRs. However, they are often complicated to generate or not
available, and, most importantly, they cannot assess PRR activation
in non-human primate or human studies.23
To overcome these limits, we used a proximity ligation assay (PLA) to
detect PRR activation in a sensitive, kinetic, and quantitative manner
by measuring the formation of speciﬁc PRR complexes. While some
proteins are ubiquitous across pathways, the complexes they form
are unique to each pathway. The formation of such complexes is
typically measured by immunoprecipitation, which lacks cell-to-
cell variability or spatial information.24 In PLA, the proteins of
interest are recognized by primary antibodies, which are then recog-
nized by detection antibodies conjugated to speciﬁc oligonucleotidesuthor(s).
ecommons.org/licenses/by/4.0/).
Figure 1. PRR Activation Pathways and PLA
Experimental Design
(A) Schematic representation of relevant TLR7, RIG-I,
MDA5, and TLR4 immune pathways. (B) Schematic rep-
resentation of PLA methodology.
www.moleculartherapy.org(Figure 1B). If the proteins are within 40 nm, the addition of a ligase
and complementary oligonucleotides forms a circle, which is ampli-
ﬁed by rolling circle ampliﬁcation. The ampliﬁcation product is
detected in situ with ﬂuorescent oligonucleotides. PLA is sensitive,
due to the need of close proximity, and quantitative, as the PLA
puncta are measurable. PLA can be used in tissue sections, which is
critical for clinical studies.25,26 We have formerly demonstrated the
use of PLA to measure protein-protein interactions, including
MDA5 and mitochondrial antiviral-signaling protein (MAVS), as
well as protein-RNA interactions.27–30 PLA has also been successfully
used to proﬁle cell-signaling pathways and measure cytokine produc-
tion and receptor dimerization.31–33 However, none of these previous
studies used PLA to look at the early stages of PRR activation, espe-
cially in an in vivo context.
Here we applied PLA to the study of immune responses elicited by an
in vitro-transcribed (IVT) mRNA vaccine model, in both a cellular
model and in vivo mouse studies. IVT mRNA encodes for the anti-
genic protein(s) and is concurrently detected by anti-viral PRRs,Molecularwhich activate innate immune responses, facili-
tating the development of protective immune re-
sponses.17–19,34–39 By pre-labeling IVT mRNA
with multiply labeled tetravalent RNA imaging
probes (MTRIPs), its distribution can be assessed
by confocal microscopy without affecting meta-
bolism, localization, or translatability.30,40 The
colocalization of mRNA and PLA signals allows
the correlation of immune responses in cells
and tissue with downstream immune function.
We strongly believe that this approach provides
a valuable tool to assess the effect of adjuvants,
vaccines, and formulations both in vitro and
in vivo during development and screening.
RESULTS
PLA Specifically Detects the Activation of
Unique PRR Pathways In Vitro
PLA’s efﬁciency and speciﬁcity in detecting PRR
activation pathways were ﬁrst assessed in vitro
by quantifying TLR7, RIG-I, MDA5, or TLR4
complex formation. Upon activation, TLR7 com-
plexes with myeloid differentiation response gene
88 (MyD88). MyD88 then interacts with the
interleukin-1 receptor-associated kinase proteins
(IRAK1, IRAK2, and IRAK4), forming the myd-
dosome and beginning a pathway that leads to
type I IFN and inﬂammatory cytokine induction.TLR4 can associate with MyD88 and TIR-domain-containing
adaptor protein (TIRAP) and follow similar pathways to lead to in-
ﬂammatory cytokine production. TLR4 also induces type I IFN
through a MyD88-independent pathway by associating with TIR-
domain-containing-adaptor protein-inducing IFN-b (TRIF) and
TRIF-related adaptor molecule (TRAM).1,2,4,5,13–17,41 For cyto-
plasmic PRRs, both RIG-I and MDA5 associate with interferon-
beta promoter stimulator 1 (IPS-1), also known as MAVS, leading
to the induction of type I IFN and inﬂammatory cytokines (Fig-
ure 1A).1,5,13,17,18 As a result, we chose to quantify the following
interactions to distinguish between the PRR pathways: TLR7-
IRAK4, RIG-I-MAVS, MDA5-MAVS, TLR4-TIRAP, and TLR4-
TRAM.
Activation of TLR7, RIG-I, and MDA5 was induced via IVT mRNA
transfection. As TLR4 is not stimulated by nucleic acids, lipopolysac-
charide (LPS) was used as an agonist. PRR activation was quantiﬁed
in wild-type (WT) cells and cells expressing modulated PRR levels.
TLR7 PLA was evaluated in NIH/3T3 cells, which naturally expressTherapy: Nucleic Acids Vol. 14 March 2019 53
Figure 2. PLA Detection of PRR Activation in Cells with Modulated PRR Expression Levels
(A) NIH/3T3 cells were transfected with or without TLR7 via electroporation. After 48 hr, cells were transfected with or without 2.5 mg luciferase mRNA by Lipofectamine 2000
(L2K). Cells were fixed after 24 hr with 1% paraformaldehyde, and PLA was performed between TLR7 and IRAK4. Representative images of PLA (white) and quantification of
PLA are shown. Extended focus images are shown. Scale bars, 10 mm. Statistics were performed with a one-way ANOVA with a Dunn’s multiple comparisons test, where
n = 30 and ****p < 0.0001. 95% confidence intervals are shown in red. (B) RAW-Lucia ISGmacrophages, WT, RIG-I KO, or MDA5 KO, were transfected with or without 2.5 mg
luciferase mRNA by Lipofectamine 2000. Cells were fixed after 24 hr with ice-cold methanol, and PLA was performed between RIG-I and MAVS or MDA5 and MAVS.
Representative images of PLA (white) and quantification of PLA are shown. Extended focus images are shown. Scale bars, 10 mm. Statistics were performed with a one-way
ANOVA with a Dunn’s multiple comparisons test, where n = 30 and *p < 0.035. 95% confidence intervals are shown in red. (C) RAW 264.7 macrophages were transfected
(legend continued on next page)
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www.moleculartherapy.orglow levels of TLR7, and in cells transfected with a TLR7-encoding
plasmid. RIG-I and MDA5 activation was assayed in RAW-Lucia
ISG macrophages, using either the WT cell line or the commercially
available RIG-I- or MDA5-KO cell lines. As TLR4-KO cells were not
readily available, small interfering RNA (siRNA) was used to knock
down TLR4 in RAW 264.7 macrophages for comparison with WT
cells. Lipofectamine-only controls were included in each condition.
TLR7-IRAK4 interactions were signiﬁcantly higher in cells that
were both stimulated by IVT mRNA and that expressed high levels
of TLR7, in comparison to cells with basal levels of TLR7 or unstimu-
lated cells (Figure 2A). Similar results were observed for RIG-I and
MDA5 interactions with MAVS (Figure 2B). In both assays, WT cells
stimulated with IVT mRNA generated a signiﬁcantly higher number
of interactions than KO cells or unstimulated WT cells. Accordingly,
cells treated with TLR4 siRNA displayed signiﬁcantly fewer interac-
tions with TIRAP or TRAM (Figure 2C). These results demonstrated
the speciﬁcity of the PLA methodology to detect PRR activation
through the quantiﬁcation of PRR protein complex formation.
PLA Sensitively Detects Kinetic Changes in PRR Pathway
Activation In Vitro
We subsequently evaluated PLA’s ability to sensitively measure PRR
activation kinetics. Well-characterized soluble PRR agonists were
delivered to RAW 264.7 macrophages, and PRR activation-induced
complexes were measured over several time points. 8 mg/mL imiqui-
mod was used to activate TLR7, 10 mg/mL 50ppp dsRNA was used to
activate RIG-I, while 0.1 mg/mL polyinosinic:polycytidylic acid
[poly(I:C)] was utilized as an MDA5 agonist. 1 mg/mL LPS was
used to stimulate the TLR4-TIRAP pathway, while 10 mg/mL LPS
was used to stimulate the TLR4-TRAM pathway. To assess kinetics,
PRR activation was measured at 30 min and 6 hr after delivery of
the agonists. Additionally, at 6 hr, the agonists were removed, and
the cells were incubated with fresh media for 3 hr to allow for the re-
covery of base levels of PRR activation. PRR activation was detected
for TLR7, RIG-I, MDA5, and both TLR4 pathways as early as
30 min after agonist delivery (Figures 3A and S1). At 6 hr post-deliv-
ery, the number of interactions signiﬁcantly increased for TLR7,
RIG-I, and MDA5, indicating that an ampliﬁed PRR response
occurred as time progressed. Finally, when the agonists were removed
and the cells were allowed to recover, the number of interactions for
TLR7, RIG-I, and MDA5 signiﬁcantly decreased, with TLR7 and
RIG-I displaying no signiﬁcant activation. TLR4 interactions with
TIRAP or TRAM decreased 6 hr post-delivery and were not affected
by recovery. These results demonstrated PLA’s sensitivity in detecting
the expected changes of activation over time in response to known
agonists.
By ﬂuorescently labeling organelles prior to PLA, we demonstrated
the colocalization of PLA puncta with endosomes and mitochondriawith or without 100 nM TLR4 siRNA via Lipofectamine 2000. After 24 hr, cells were incu
After 30min, cells were fixed with 1% paraformaldehyde, and PLA was performed betwe
quantification of PLA are shown. Extended focus images are shown. Scale bars, 10 m
parisons test, where n = 30 and ****p < 0.0001. 95% confidence intervals are shown in(Figure 3B). TLR7-IRAK4 and TLR4-TRAM interactions occur on
endosomal membranes; accordingly, PLA puncta were visualized
immediately adjacent to endosomes. Conversely, PLA puncta for
TLR4-TIRAP interactions, which occur on the cell membrane, did
not colocalize with endosomes. MAVS is localized on the mitochon-
dria membranes; accordingly, RIG-I-MAVS and MDA5-MAVS in-
teractions colocalized with mitochondria staining.42 It is important
to note that PLA puncta are generated by rolling circle ampliﬁcation,
which results in the synthesis of a long DNA chain. Consequently, the
puncta can slightly diffuse around the origin point (the location of the
interacting protein pair), so perfect colocalization with endosomes or
mitochondria was not expected. These results validated that the PLA
method successfully detects the indicated interactions in proximity to
the expected cellular compartments.
Next, we compared PRR activation by PLA to tumor necrosis factor
alpha (TNF-a) production by ELISA. RAW 264.7 macrophages
were stimulated with 8 mg/mL imiquimod, 10 mg/mL 50ppp dsRNA,
0.1 mg/mL poly(I:C), and 1 or 10 mg/mL LPS. Supernatants were
collected and cells were ﬁxed at 30 min or 6 or 24 hr post-stimula-
tion. An ELISA was performed for each time point (Figure 3C).
TNF-a production by ELISA was detected at 6 and 24 hr, while
no TNF-a was detected at 30 min. Importantly, all agonists stimu-
lated TNF-a release. PRR activation was detected by PLA as early as
30 min post-treatment (Figures 3A and 3D).
Critically, only the expected agonists triggered speciﬁc pathways
when measured by PLA, with the exception of TLR7-IRAK4, whose
activation was also observed upon the delivery of poly(I:C), likely
due to the transfection agent needed for its cellular entry. These
data demonstrate that PLA is superior to conventional methods,
such as ELISAs, due to its ability to isolate speciﬁc pathways, as
well as to detect early activation kinetics.
PLA Detects Differences in PRR Pathway Activation Induced by
Modified Nucleosides of IVT mRNA
We next explored PLA’s sensitivity in quantifying innate immune
responses to delivered IVT mRNA. It has been shown that incorpo-
rating modiﬁed nucleosides into IVT mRNA reduces PRR activa-
tion.10,11 Therefore, we quantiﬁed PRR activation via PLA upon
delivery of either unmodiﬁed or modiﬁed IVT GFP mRNA. mRNA
was transfected into RAW 264.7 macrophages with Lipofectamine
2000, and cells were ﬁxed at either 30 min or 24 hr post-delivery.
While neither mRNA activated a RIG-I response, unmodiﬁed
mRNA induced a signiﬁcantly higher TLR7 activation at 30 min
and MDA5 activation at 24 hr (Figures 4A and S2). This activation
pattern is expected, due to the entry pathway of mRNA via Lipo-
fectamine, which proceeds through the endocytic compartment.
Therefore, the mRNA interacts with membrane-bound PRRs ﬁrst,bated with either 1 or 10 mg/mL LPS for TIRAP and TRAM interactions, respectively.
en TLR4 and TIRAP and TLR4 and TRAM. Representative images of PLA (white) and
m. Statistics were performed with a one-way ANOVA with a Dunn’s multiple com-
red.
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Figure 3. PLA Sensitively Detects PRR Activation Kinetics
(A) RAW 264.7 macrophages were incubated with the following agonists: 8 mg/mL imiquimod for TLR7, 10 mg/mL 50ppp dsRNA for RIG-I, 0.1 mg/mL poly(I:C) for MDA5,
1 mg/mL LPS for TLR4-TIRAP, and 10 mg/mL LPS for TLR4-TRAM. Cells were fixedwith 1%paraformaldehyde ormethanol as previously indicated after 30min or 6 hr. Also at
6 hr, agonists were removed and cells were incubated with media for 3 additional hours before fixing. PLAwas performed between TLR7-IRAK4, RIG-I-MAVS, MDA5-MAVS,
TLR4-TIRAP, and TLR4-TRAM. Representative images of PLA (white) and quantification of PLA are shown. Extended focus images are shown. Scale bars, 10 mm. Statistics
were performed with a two-way ANOVAwith a Tukey’s multiple comparisons test, where n = 30 and *p < 0.031, ****p < 0.0007, and ****p < 0.0001. 95% confidence intervals
are shown in black. (B) A549 cells for TLR7-IRAK4, TLR4-TIRAP, and TLR4-TRAMPLAswere transfected with CellLight Early Endosomes-GFP-BacMam2.0 for 16 hr prior to
stimulation with 8 mg/mL imiquimod for TLR7 or 1 mg/mL LPS for TLR4-TIRAP and 10 mg/mL LPS for TLR4-TRAM for 30min before fixation with 1% paraformaldehyde. RAW
264.7 macrophages for RIG-I-MAVS and MDA5-MAVS PLAs were incubated with MitoTracker for 15 min prior to stimulation with 0.1 mg/mL poly(I:C) for RIG-I or MDA5 for
30 min before fixation with methanol. PLA was performed between TLR7-IRAK4, RIG-I-MAVS, MDA5-MAVS, TLR4-TIRAP, and TLR4-TRAM. Representative images of PLA
(red) and either endosomes (green) (TLR7-IRAK4, TLR4-TIRAP, and TLR4-TRAM) or mitochondria (green) (RIG-I-MAVS and MDA5-MAVS) are shown. Extended focus
images are shown. Scale bars, 10 mm. (C and D) RAW 264.7 macrophages were incubated with the following agonists: 8 mg/mL imquimod, 10 mg/mL 50ppp dsRNA,
0.1 mg/mL poly(I:C), and 1 or 10 mg/mL LPS. Supernatants were collected, and cells were fixed with 1% paraformaldehyde or methanol as previously indicated after 30min or
6 or 24 hr. (C) An ELISA for TNF-a was performed on supernatants. Quantification is shown with SDs in black. Statistics were performed with a two-way ANOVA with a
Tukey’s multiple comparisons test, where n = 2 and *p < 0.007 and ****p < 0.0001. (D) PLA was performed at the 30-min time point for TLR7-IRAK4, RIG-I-MAVS, MDA5-
MAVS, TLR4-TIRAP, and TLR4-TRAM. Quantification is shown, with 95% confidence intervals in black. Statistics were performed with a two-way ANOVA and a Tukey’s
multiple comparisons test, where n = 30 and *p < 0.01, **p < 0.007, and ****p < 0.0001.
Molecular Therapy: Nucleic Acidsis internalized in endocytic vesicles, and is then released into the
cytosol, where it interacts with cytoplasmic PRRs such as RIG-I and
MDA5.43–45 This demonstrates PLA’s ability to detect the changes
in PRR activation due to base modiﬁcations in IVT mRNA. It should
be noted that TLR4 activation was not measured, as mRNA is not one
of its agonists.
PLA Measures the Difference in PRR Pathway Activation
between IVT mRNA Sequences
We also examined PLA’s sensitivity in quantifying PRR activation
due to different IVT mRNA sequences. GFP- or luciferase-encoding
IVT mRNA, both containing modiﬁed nucleosides but with different
30 UTRs and coding regions, was delivered to RAW 264.7 macro-
phages with Lipofectamine 2000 and ﬁxed after 30 min and 6 hr. Dif-
ferences in IFN-a production between GFP and luciferase mRNAs
have previously been discussed in the literature with both unmodiﬁed
and modiﬁed mRNAs.46 GFP mRNA induced a fast and strong TLR7
response at 30 min, which ceased by 6 hr post-delivery. Conversely,56 Molecular Therapy: Nucleic Acids Vol. 14 March 2019luciferase mRNA induced a strong TLR7 response that persisted up
to 6 hr post-delivery and a rapid, strong RIG-I response at 30 min
post-transfection (Figures 4B and S2). Overall, these data indicate
that different mRNAs induce the activation of alternative PRR path-
ways, which can be speciﬁcally identiﬁed and monitored using PLA.
PLA Detects PRR Pathway Activation In Vivo in Muscle Tissue
Next, we aimed to quantify PRR activation via PLA in muscle tissue
after intramuscular delivery of mRNA in mice. To visualize mRNA
distribution in the muscle, IVT mRNA encoding for ﬁreﬂy luciferase
was pre-labeled with MTRIPs targeting three regions within the
30 UTR (Figures S3A and S3B). MTRIP labeling did not affect PRR
activation upon transfection in RAW 264.7 cells with modiﬁed or
unmodiﬁed IVT GFP mRNA (Figure S4).
IVT mRNA was injected intramuscularly (i.m.) either naked or
formulated with the nanoparticle CholK, for improved delivery, espe-
cially to lymph nodes over naked delivery.40 At 1.5 hr following
Figure 4. Differences in PRR Activation between Unmodified and Modified IVT mRNAs and between mRNA Sequences
(A) RAW 264.7 macrophages were untreated, transfected with Lipofectamine 2000 (L2K) alone, or transfected with 200 ng unmodified or modified IVT GFP mRNA via
L2K. Cells were fixed with either 1% paraformaldehyde or methanol after 30 min or 24 hr. Representative images of PLA (white) and quantification of PLA puncta per cell are
shown. Extended focus images are shown. Scale bars, 10 mm. Statistics were performedwith a two-way ANOVAwith a Tukey’s multiple comparisons test, where n = 30 and
****p < 0.0001. 95% confidence intervals are shown in black. (B) RAW 264.7 macrophages were untreated, transfected with Lipofectamine 2000 (L2K) alone, or transfected
with 200 ng modified IVT GFP or luciferase mRNA via L2K. Cells were fixed with either 1% paraformaldehyde or methanol after 30 min or 6 hr. Representative images of PLA
(white) and quantification of PLA are shown. Extended focus images are show. Scale bars, 10 mm. Statistics were performed with a two-way ANOVA with a Tukey’s multiple
comparisons test, where n = 30 and *p < 0.045 and ****p < 0.0001. 95% confidence intervals are shown in black.
www.moleculartherapy.orginjection, IVT mRNA delivered alone or complexed to CholK was
evenly distributed throughout the muscle, primarily between skeletal
muscle ﬁbers. At 16 hr following injection, naked IVT mRNA levels
decreased signiﬁcantly in the muscle, potentially as a consequence
of mRNA degradation, while mRNA complexed with CholK re-
mained present throughout the tissue (Figure S5A). We assessedexpression of TLR7, RIG-I, and MDA5 via immunoﬂuorescence
staining in skeletal muscle tissue following the injection with either
naked IVT mRNA or a sham control. Upregulated PRR expression
was observed via immunoﬂuorescence in these tissues 16 hr following
the injection of ﬂuorescently labeled naked IVT mRNA, in compari-
son to sham-injected muscle (Figures S6 and S7). We observed thatMolecular Therapy: Nucleic Acids Vol. 14 March 2019 57
Figure 5. TLR7 Activation by PLA in Muscle Tissue
Representative images of TLR7-IRAK4 PLA (white) 6 hr
following i.m. injection into the anterior tibialis of 10 mg
luciferase IVT mRNA (red) unformulated or formulated with
CholK. Extended focus images are shown. Scale bars,
20 mm (full images) and 5 mm (crops). White boxes show
cropped selection. Quantification of TLR7-IRAK4 PLA is
shown. Statistics were performed with a two-way ANOVA
with a Tukey’s multiple comparisons test, where n = 30,
except for sham 1.5 hr where n = 12, and *p < 0.04 and
***p < 0.0004. 95% confidence intervals are shown in black.
Molecular Therapy: Nucleic Acidscells with elevated PRR levels were distributed throughout the skeletal
muscle tissue and that these cell types were associated with IVT
mRNA. To assess the uptake of IVT mRNA into immune cells
16 hr following injection, ﬂow cytometry was performed. IVT
mRNA injection led to an increased presence of CD11b+ cells in
the muscle (Figure S5B). Mice injected with IVT mRNA complexed
with CholK also showed increased levels of MHCII+ cells, as well as
inﬁltration of natural killer cells, identiﬁed by the dual staining of
CD335 and CD11b.
Based on the upregulated expression of PRRs as evidenced by immu-
noﬂuorescence, as well as by the uptake of mRNA by inﬁltrating im-
mune cells, we next examined the PRR response via PLA at 1.5, 6, and
16 hr following i.m. injection of ﬂuorescently labeled IVT mRNA,
either naked or complexed with CholK, as well as after a sham injec-
tion. We noticed that, in tissue sections, PRR activation did not result
in the formation of single PLA puncta but rather in large aggregates.
Therefore, PRR activation was quantiﬁed by measuring the total PLA
signal volume.
Naked mRNA induced signiﬁcant TLR7 activation at 6 hr and RIG-I
activation at 16 hr post-delivery, respectively (Figures 5 and 6; Fig-
ure S8). mRNA formulated with CholK induced a signiﬁcant TLR7
activation at 6 hr, RIGI activation at 6 and 16 hr, and MDA5 activa-
tion at 16 hr post-delivery (Figures 5, 6, and 7; Figure S8), consistent58 Molecular Therapy: Nucleic Acids Vol. 14 March 2019with the observed prolonged retention of the IVT
mRNA within tissue (Figure S5A). PLA signal
was clearly observed in close proximity to deliv-
ered mRNA, demonstrating that the PRR activa-
tion occurred primarily in cells that internalized
mRNA and not uniformly across the tissue.
PLA Detects PRR Activation In Vivo in Lymph
Nodes after i.m. Injection
Following i.m. injection of ﬂuorescently labeled
IVT mRNA, the Fluobeam imaging system
(Fluoptics) was used on euthanized mice to deter-
mine IVT mRNA trafﬁcking to the draining
lymph nodes (Figure S9) and, speciﬁcally, to the
lumbar aortic, inguinal, and popliteal lymph no-
des. Lymph nodes were histologically analyzedto assess IVTmRNA distribution (Figures S10A–S10C). In tissue sec-
tions, IVTmRNAwas observed around and within the lymphatic ves-
sels stained for Lyve-1. Isolated lymph nodes were homogenized to
identify the cell types positive for IVT mRNA based on their cell sur-
face markers by ﬂow cytometry (Figure S10D). IVT mRNA was
largely present in antigen-presenting cells, such as MHCII+,
CD11b+, and CD19+CD3 (B cell) lymph node cells. Next, PRR acti-
vation was assessed in the lumbar aortic lymph nodes excised 16 hr
post-injection (Figure 8). Both naked and CholK-delivered IVT
mRNA signiﬁcantly induced the activation of TLR7 and MDA5.
These results highlight PLA versatility in detecting PRR activation
across multiple tissues types.
DISCUSSION
Here we demonstrated the use of PLA as a sensitive, quantitative, and
speciﬁc tool to measure PRR activation in cells and in tissue upon IVT
mRNA delivery. First, we compared PRR activation with modulated
protein levels in vitro, as well as over time in response to known ag-
onists. This validated the speciﬁcity of PLA to detect individual PRR
pathways, as interactions unique to each pathway were identiﬁed and
quantiﬁed, indicating both the antibodies’ speciﬁcity for the target
complex molecules and the assay’s speciﬁcity for complex formation.
Furthermore, this demonstrated the versatility of PLA, as it was suc-
cessfully optimized for several PRR pathways whose activation
occurred in distinct cellular compartments: TLR4 on the cell surface
Figure 6. RIG-I Activation by PLA in Muscle Tissue
Representative images of RIG-I-MAVS PLA (white) 6 hr
following i.m. injection into the anterior tibialis of 10 mg
luciferase IVT mRNA (red) unformulated or formulated with
CholK. Extended focus images are shown. Scale bars,
20 mm (full images) and 5 mm (crops). White boxes show
cropped selection. Quantification of RIG-I-MAVS PLA is
shown. Statistics were performed with a two-way ANOVA
with a Tukey’s multiple comparisons test, where n = 30 and
*p < 0.03 and ***p < 0.0007. 95% confidence intervals are
shown in black.
www.moleculartherapy.orgmembrane, TLR7 in the endosome, and RIG-I andMDA5 in the cyto-
plasm. Immunoﬂuorescence colocalization of PLA puncta with
cellular organelles further veriﬁed the ability of PLA to distinguish be-
tween pathways in different cellular compartments. This provides
support to the translatability of PLA to detect other PRR pathways
not detailed in this work.
PLA was also shown to be able to distinguish TLR4 sub-pathways,
conﬁrming its ability to isolate unique activation routes. Moreover,
PLA successfully detected activation kinetics and quantitatively
measured the turning on and turning off of individual PRR pathways
in vitro. This sensitivity is critical because the formation of these com-
plexes is transient and unique to each pathway. PLA was able to spe-
ciﬁcally identify the individual pathway, as interactions for each
pathway were not detected if non-expected agonists were used.
Furthermore, the results support the sensitivity of PLA to distinguish
levels of PRR activation over time at earlier time points than ELISAs.
Comparing the strength of responses induced by two candidate ago-
nists, for example, would provide critical information during vaccine
and therapeutic development.
Subsequently, we examined PLA’s suitability in measuring the PRR
response of synthetic IVT mRNAs. We compared unmodiﬁed
mRNA to mRNA with modiﬁed nucleosides previously seen to be
immunomodulatory.10,11 These results conﬁrm PLA can be used to
screen IVTmRNA for PRR activation, as it conﬁrms the previously re-Molecularported modulatory effect of modiﬁed nucleosides
in IVT mRNA. The difference in activation times
between the PRRs ismost likely due to the delivery
method. As Lipofectamine prompts internaliza-
tion via endosomes,43–45 the IVTmRNA interacts
with TLR7 earlier than MDA5, which is cyto-
plasmic and ﬁrst requires mRNA escape from
the endosomal compartment.
We also demonstrated that PLA can measure dif-
ferences in PRR activation induced by two model
reporter mRNAs. We conﬁrmed that mRNA
sequence is a determinant in PRR activation,
supporting differences in IFN-a production pre-
viously observed in the literature.46 Despite deliv-ering equivalent amounts of mRNA, luciferase mRNA was released
from the endosome as early as 30 min and induced a signiﬁcant
RIG-I response, unlike GFP mRNA. Moreover, luciferase mRNA
was retained in the endosomes longer than GFP mRNA, as it still
produced a signiﬁcant TLR7 response at 6 hr post-delivery. These dif-
ferences are likely due to the internalization time and secondary
structure. Size difference between the mRNAs may cause a difference
in charge, affecting the complexation efﬁciency with Lipofectamine
2000.
Both charge ratio and size of lipoplexes have been observed to
affect transfection time and efﬁciency.43,47 Downstream cytokine
measurement would be insufﬁcient to compare the persistence of
the TLR7 response, as both would produce type I IFN and inﬂam-
matory cytokines. PLA, however, was able to detect shifting levels
of activation over time. The difference in RIG-I activation is likely
due to the formation of unique secondary structures in the
mRNAs as a result of their sequences, indicating that the luciferase
mRNA may have more prominent secondary structures than
GFP mRNA, or due to differences in capping efﬁciency and phos-
phatase activity for this particular mRNA.17,18,48,49 As a whole,
these results demonstrate PLA’s value in screening nucleotide-
based therapeutics and vaccines in their developing stage. RNA
vaccines for two different diseases may require different delivery
formulations to induce the same immune response and protective
immunity.Therapy: Nucleic Acids Vol. 14 March 2019 59
Figure 7. MDA5 Activation by PLA in Muscle Tissue
Representative images of MDA5-MAVS PLA (white) 16 hr
following i.m. injection into the anterior tibialis of 10 mg
luciferase IVT mRNA (red) unformulated or formulated with
CholK. Extended focus images are shown. Scale bars,
20 mm (full images) and 5 mm (crops). White boxes show
cropped selection. Quantification of MDA5-MAVS PLA is
shown. Statistics were performed with a two-way ANOVA
with a Tukey’s multiple comparisons test, where n = 30 and
****p < 0.0001. 95% confidence intervals are shown in
black.
Molecular Therapy: Nucleic AcidsAnother advantage of PLA measurements in vitro is that they could
be performed in a 96-well glass-bottom plate using the manufac-
turer’s protocol. Several interacting protein pairs can be assessed in
the same plate and imaged directly in the plate. The Volocity acqui-
sition software could be set to automatically acquire images in each
well, allowing for an automated imaging process. As a result, PLA
allows the measurement of PRR activation in a high-throughput
screening fashion, establishing it as an ideal approach to quickly char-
acterize agonist-induced PRR activation in cells prior to their use in
in vivo experiments.
We next demonstrated the use of PLA as a PRR quantiﬁcation tool
in vivo in tissue. First, we veriﬁed the successful delivery of the
IVT mRNA into muscle via i.m. injection, and we assessed the
mRNA-induced recruitment of immune cells. CholK-mediated
delivery enhanced immune cell inﬁltration over naked delivery,
as supported by ﬂow cytometry and immunoﬂuorescence. Further-
more, mRNA complexed with CholK was retained in the muscle
longer than free mRNA, inducing a stronger RIG-I response at
6 hr and a stronger MDA5 activation at 16 hr. We hypothesize
that CholK enhanced cytoplasmic delivery of the mRNAs in tissue,
causing the stronger cytoplasmic PRR responses of complexed
mRNA over naked mRNA, as supported by our prior work.40
The extended mRNA retention in the muscle tissue is likely the
main cause of MDA5 activation at 16 hr post-injection. Elevated
RIG-I and MDA5 activation from complexed mRNA could60 Molecular Therapy: Nucleic Acids Vol. 14 March 2019generate a strong type I IFN response, inducing
further immune cell recruitment.50 We also
observed that PLA signal was localized in close
proximity to the mRNA, indicating the PRR
activation was a direct result of internalized
mRNA rather than a paracrine response.
Type I IFN is also known to promote migration of
antigen-presenting cells to lymph nodes.50,51
mRNA was detected in the lymph nodes at
16 hr after i.m. injection and resulted in signiﬁ-
cant TLR7 and MDA5. Though naked mRNA
trafﬁcked to the lymph nodes and activated
PRRs, the increased inﬁltration of immune cells
in the muscle observed with CholK-formulatedmRNA most likely enhanced cell-mediated trafﬁcking of the IVT
mRNA, enhancing TLR7 activation. Trafﬁcking of antigens to the
lymph node and the subsequent PRR activation is fundamental since
the lymph node is the site of adaptive immunity initiation. Observa-
tion of PRR activation in lymph nodes is, therefore, critical in vaccine
development. Overall, these ﬁndings clearly indicate PLA is a versatile
tool that can be used across multiple tissues.
In conclusion, we demonstrated PLA’s use as a method of detection of
innate immune responses both in vitro in cells and in tissue sections.
This valuable tool allows for sensitive, speciﬁc, and quantitative
measurements of the kinetics of PRR activation. PLA can be used in
a high-throughput screeningmanner, to compare the effect ofmultiple
agonists, adjuvants, or therapies easily and rapidly in vitro. Finally, it
allows insights into the spatial context where the activation occurs,
both in single cells and across whole tissues. We believe PLA has the
potential to be a crucial tool in therapeutic and vaccine development.
MATERIALS AND METHODS
Antibodies for PLA
Primary antibodies used were as follows: mouse anti-RIG-I (sc-
376845, 1:500; Santa Cruz Biotechnology, Dallas, TX), goat anti-
MDA5 (sc-48031, 1:500; Santa Cruz Biotechnology, Dallas, TX),
rabbit anti-MAVS (IHC-00477, 1:500; Bethyl Laboratories, Mont-
gomery, TX), rabbit anti-TLR7 (NBP2-24906, 1:500; Novus Biolog-
icals, Littleton, CO), mouse anti-IRAK4 (LS BIO452, 1:500; LS Bio,
Figure 8. PRR Activation by PLA in Lymph Node Tissue
Lymph nodes were excised and fixed 16 hr following i.m. injection into the anterior tibialis of 10 mg luciferase IVT mRNA (red) unformulated or formulated with CholK.
(A) Representative images of TLR7-IRAK4 PLA (white) shown. Extended focus images are shown with 10-mm scale bars. Quantification of TLR7-IRAK4 PLA is shown.
Statistics were performed with a one-way ANOVA with a Dunn’s multiple comparisons test, where n = 30 and *p < 0.02 and ***p < 0.0002. 95% confidence intervals are
(legend continued on next page)
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Molecular Therapy: Nucleic AcidsSeattle, WA), rabbit anti-TLR4 (NB100-56581, 1:50; Novus Biolog-
icals, Littleton, CO), goat anti-TIRAP (NB300-990, 1:100; Novus Bi-
ologicals, Littleton, CO), and goat anti-TRAM (AF4348, 1:1,000;
Novus Biologicals, Littleton, CO).
In Vitro PLA on Cells with Differential TLR7 Expression
NIH/3T3 mouse ﬁbroblast cells (ATCC CRL-1658, Manassas, VA)
were maintained in High Glucose DMEM (Lonza, Allendale, NJ)
with 20% bovine calf serum (Gibco, Waltham, MA). NIH/3T3 cells
do not express detectable levels of TLR752 and were used with or
without induced expression of TLR7. NIH/3T3 cells were electropo-
rated using the Neon transfection system with 9 mg TLR7-encoding
plasmid (pUNO1-mTLR07-HA3x, InvivoGen, San Diego, CA) and
seeded onto glass coverslips in a 24-well plate. Electroporation
without any plasmid was used as the TLR7 control. After 48 hr, cells
were transfected with 2.5 mg luciferase IVT mRNA/well using Lipo-
fectamine 2000; 24 hr later, cells were ﬁxed with 1% paraformalde-
hyde in PBS for 10 min, permeabilized with 0.2% Triton X-100 in
PBS for 5 min, and then assayed for TLR7 and IRAK4 proximity.
In Vitro PLAs on Cells with Differential RIG-I and MDA5
Expression
RAW-Lucia ISG mouse macrophage cells, which express both RIG-I
and MDA5, were used as WT. RAW-Lucia ISG-KO-RIG-I cells and
RAW-Lucia ISG-KO-MDA5 cells were used as KO controls. All
RAW-Lucia ISG cell lines were purchased from InvivoGen and main-
tained in DMEM with 10% fetal bovine serum (FBS) (Hyclone, Wal-
tham, MA) and 100 mg/mL Normocin (InvivoGen, San Diego, CA).
In all cases, cells were seeded onto glass coverslips in a 24-well plate
and transfected with 2.5 mg luciferase IVT mRNA per well using Lip-
ofectamine 2000. Cells were ﬁxed with ice-cold methanol at 24 hr
following IVT mRNA transfection for 15 min at 20C, permeabi-
lized with 0.2% Tween-20 for 5 min, and then assayed for RIG-I
and MDA5 proximity with MAVS. We found that methanol ﬁxation,
rather than paraformaldehyde ﬁxation, was essential for performing
the MDA5 and RIG-I PLAs (data not shown).
In Vitro PLAs on Cells with Differential TLR4 Expression
RAW 264.7 macrophages (ATCC, Manassas, VA), a commonly used
cell line for studying the immune response, were used. They were
maintained in DMEM with 10% FBS and 1% penicillin streptomycin
(PS) (Thermo Fisher Scientiﬁc,Waltham,MA). Cells were transfected
with and without 100 nM TLR4 siRNA (Thermo Fisher Scientiﬁc,
Waltham, MA) delivered with Lipofectamine 2000. Cells were plated
in a 96-well glass-bottom plate. 24 hr after siRNA delivery, 1 mg/mL
LPS was added to TLR4-TIRAP conditions and 10 mg/mL was added
to TLR4-TRAM conditions. After 30 min, cells were ﬁxed with 1%
paraformaldehyde in PBS for 10 min, permeabilized with 0.2% Tritonshown in red. (B) Representative images of RIG-I-MAVS PLA (white) shown. Extended f
shown. Statistics were performed with a one-way ANOVA with a Dunn’s multiple c
Representative images of MDA5-MAVSPLA (white) shown. Extended focus images are s
were performed with a one-way ANOVA with a Dunn’s multiple comparisons test, wher
95% confidence intervals are shown in red.
62 Molecular Therapy: Nucleic Acids Vol. 14 March 2019X-100 in PBS for 5 min, and then assayed for TLR4 proximity with
TIRAP or TRAM.
In Vitro PLA Procedure
After permeabilization, cells were blocked against nonspeciﬁc binding
with 1%BSA, 2%donkey serum, and 0.2% gelatin in 1PBS for 30min
at 37C. Primary antibodies were then incubated with cells in 1% BSA,
0.2% donkey serum, and 0.2% gelatin in 1 PBS at the indicated con-
centrations for 30 min at 37C. Cells were washed in wash buffer A
(Sigma-Aldrich, St. Louis, MO) for 10 min at room temperature
(RT) and incubated with secondary antibodies (Sigma-Aldrich, St.
Louis, MO) at manufacturer-recommended concentrations in 0.2%
Tween-20 in 1 PBS for 30 min at 37C. Cells were again washed in
wash buffer A for 10 min at RT and then incubated with the ligase
and ligase buffer, as speciﬁed by the manufacturer (Sigma-Aldrich,
St. Louis, MO) for 30 min at 37C. Next, cells were washed in wash
buffer A for 10 min at RT and incubated with the polymerase and roll-
ing circle ampliﬁcation buffer, as speciﬁedby themanufacturer (Sigma-
Aldrich, St. Louis, MO) for 100min at 37C. Finally, cells were washed
in wash buffer B (Sigma-Aldrich, St. Louis, MO) for 20 min at RT and
then 0.01 buffer B for 4 min at RT. Mounting medium with DAPI
(Sigma-Aldrich, St. Louis, MO) was added and cells were imaged.
Fluorescence Imaging
In vitro images were taken using a Hamamatsu Flash 4.0 version (v.)2
sCMOS camera on a PerkinElmer UltraView spinning-disk confocal
microscope on a Zeiss Axiovert 200 M body. A 63, numerical
aperture (NA) 1.4 Zeiss Plan-Apochromat oil objective was used
for all images. Imaging was controlled by Volocity acquisition soft-
ware (PerkinElmer, Waltham, MA). Image stacks were recorded at
200-nm intervals.
In Vitro PLA Quantification and Statistics
After images were acquired, Volocity acquisition software was used to
draw regions of interest (ROIs) around each cell.Volocity software then
was used to quantify the number of ﬂuorescent puncta in each ROI
above a speciﬁed signal threshold. Thirty cells were counted for each
experimental condition. Twodifferent statisticsmethodswere used, de-
pending on the number of time points in the experiment. For single-
time point experiments, a one-way Kruskal-Wallis ANOVA test was
used with a Dunn’s multiple comparisons test. Formultiple-time point
experiments, a two-way ANOVA was used with a Tukey’s multiple
comparisons test. Statistics were performed in GraphPad Prism 7.0.
In Vitro PLA Time Courses for Soluble Agonists
RAW 264.7 macrophages were plated in a 96-well glass-bottom
plate. Soluble agonists included 8 mg/mL imiquimod (Sigma-Al-
drich,St. Louis, MO) for TLR7, 10 mg/mL 50ppp dsRNA and LyoVecocus images are shown with 10 mm scale bars. Quantification of RIG-I-MAVS PLA is
omparisons test, where n = 30. 95% confidence intervals are shown in red. (C)
hownwith 10 mmscale bars. Quantification of MDA5-MAVSPLA is shown. Statistics
e n = 30, except for the mRNA + CholK condition where n = 18, and ****p < 0.0001.
Table 1. List of Oligonucleotide Sequences
Target Sequence
Luciferase probe 1
50-
TTTT*TTTUAT*UCUCAT*GGUAGGCT*GA-
30
Luciferase probe 2
50-TTTT*TTTGAT*GAAUAAGCT*AUUGAT*-
30
Luciferase probe 3
50-
TTTT*TTTACAGGGT*GUUGGCT*UUACA-30
GFP probe 1
50-T*TTTTTT*GCAAGCCCC-GCAGAAGGT*-
30
GFP probe 2 50-T*TTATTT*AGAGAAGAAGGGCAT*GG-30
GFP probe 3
50-T*TTTTT*ACCAAGAGG-T*ACAGGT*GC-
30
GFP probe 4 50-T*TTTTTTCT*ACUCAGGCT*UUAUT*C-30
Boldface type indicates 20-O-methyl RNA linkage, and T* indicates a thymine base with
a C6-amino modiﬁcation.
www.moleculartherapy.org(InvivoGen, San Diego, CA) for RIG-I, 0.1 mg/mL poly(I:C) and
LyoVec (InvivoGen, San Diego, CA) for MDA5 agonist, 1 mg/mL
LPS (Sigma-Aldrich, St. Louis, MO) for the TLR4-TIRAP pathway,
and 10 mg/mL LPS (Sigma-Aldrich, St. Louis, MO) for the TLR4-
TRAM pathway. Cells were ﬁxed at 30 min and 6 hr after delivery
with 1% paraformaldehyde for 10 min for TLR7 and TLR4 or ice-
cold methanol at 20C for 20 min for RIG-I and MDA5. Also at
6 hr, agonists were removed and fresh media were added to cells
for 3 hr before ﬁxing with paraformaldehyde or methanol. Cells
were then permeablized as before and assayed for their respective
interactions.Immunofluoresence Colocalization with PLA
A549 cells (ATCC, Manassas, VA) were incubated with CellLight
Early Endosome-GFP, BacMAM 2.0 (Thermo Fisher Scientiﬁc, Wal-
tham, MA) at 50 particles per cell for 16 hr prior to stimulation. Cells
were then stimulated as indicated above for TLR7 and TLR4 and ﬁxed
30 min post-delivery with 1% paraformaldehyde for 10 min. Cells
were then permeablized as before and assayed for their respective in-
teractions. RAW 264.7 macrophages were incubated with 200 nM
MitoTracker Deep Red FM (Thermo Fisher Scientiﬁc, Waltham,
MA) for 15 min and then stimulated with 0.1 mg/mL poly(I:C) and
LyoVec for 30 min before ﬁxation with ice-cold methanol at 20C
for 20 min. Cells were then permeablized as before and assayed for
their RIG-I or MDA5 interactions.TNF-a ELISA
RAW 264.7 macrophages were plated in a 96-well glass-bottom
plate. Soluble agonists included the following: 8 mg/mL imiquimod
(Sigma-Aldrich, St. Louis, MO), 10 mg/mL 50ppp dsRNA and
LyoVec (InvivoGen, San Diego, CA), 0.1 mg/mL poly(I:C) and
LyoVec (InvivoGen, San Diego, CA), and 1 and 10 mg/mL LPS
(Sigma-Aldrich, St. Louis, MO). Supernatants were collected at
30 min and 6 and 24 hr post-stimulation before ﬁxation, as previouslydescribed. A TNF-a ELISA (R&D Systems, Minneapolis, MN) on the
supernatants was then performed according to the manufacturer’s
instructions.
IVT mRNA
IVT mRNA encoding ﬁreﬂy luciferase was provided by CureVac AG
(Tübingen, Germany). It included a 50 cap, the 30 UTR from human
albumin, as well as a poly(A) tail. All GFP mRNA contained identical
sequences, a 50 cap, the 30 UTR sequence from mouse alpha globin,
and a poly(A) tail. If modiﬁed, IVT mRNAs were made with 5-meth-
ylcytosine and pseudouridine.
In Vitro PLA Time Courses for IVT mRNA
RAW 264.7 macrophages were plated in a 96-well glass-bottom plate.
200 ng per well of modiﬁed IVT luciferase mRNA, modiﬁed IVT GFP
mRNA, or unmodiﬁed IVT GFP mRNA was delivered with Lipofect-
amine 2000. Cells were ﬁxed, permeablized, and assayed for interac-
tions at 30 min or 6 or 24 hr after delivery, as previously detailed.
MTRIP Labeling of IVT mRNA
Luciferase IVT mRNA for in vivo experiments was labeled with
MTRIPs for the detection by histology. A cartoon showing MTRIP
assembly is shown in Figure S3A, and more detailed procedures for
synthesis of MTRIPs and IVT mRNA labeling are described in previ-
ous work.30,53 Brieﬂy, 20O-methyl DNA chimeras, complementary to
three different regions of the 30 UTR of the luciferase IVT mRNA or
four different sequences of the 30 UTR of the GFP IVT mRNA, were
purchased from Biosearch Technologies (Petaluma, CA) (Table 1).
Each oligo also contained a 50 biotin. First, free amine groups were
labeled with either Cy3B N-hydroxysuccinimide (NHS) ester (GE
Healthcare, Chicago, IL) or DyLight 680 NHS ester (Pierce, Waltham,
MA), according to the manufacturers’ protocols, and unbound
dye was removed by centrifugal ﬁltration (3 kDa molecular weight
cut-off [MWCO], Millipore, St. Louis, MO). To assemble MTRIPs,
each ﬂuorescently labeled biotinylated oligo was incubated with Neu-
travidin at a 5:1 molar ratio for 1 hr at RT. Unbound oligos were then
removed by centrifugal ﬁltration (30 kDa MWCO, Millipore, St.
Louis, MO). To label IVT mRNA with MTRIPs, IVT mRNA was ﬁrst
incubated at 70C for 10 min and then immediately placed on ice to
remove secondary structures. IVT mRNA was then incubated with
each MTRIP at a 1:1 molar ratio overnight at 37C. Unlabeled probes
were removed by ﬁltration (200 kDa MWCO, Cole-Parmer, Vernon
Hills, IL), and IVT mRNA was buffer exchanged into Ringer’s lactate
(RiLa). The mRNA concentration was determined by 260-nm absor-
bance using the Nanodrop 2000 (Thermo Scientiﬁc, Waltham, MA).
Preparation of CholK
CholK was prepared in ﬁve steps starting from Kanamycin A, accord-
ing to the schematic described in Figure S3C and the procedures
described below, which are adapted from Sainlos et al.54
Kanamycin-Cbz-Teoc3 3
Kanamycin A (1.15 g, 2.38 mmol, 1 equivalent [eq.]) was dissolved in
water (10 mL). Et3N (0.33 mL, 2.38 mmol, 1 eq.) and a solution ofMolecular Therapy: Nucleic Acids Vol. 14 March 2019 63
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2.38mmol, 1 eq.) in dimethylformamide (DMF) (15mL) were succes-
sively added, and themixture was stirred at RT for 24 hr. A solution of
2-(trimethylsilyl)ethyl-4-nitrophenylcarbonate (2.30 g, 9.76 mmol,
4.1 eq.) in DMF (20 mL) and more Et3N (1.36 mL, 9.76 mmol, 4.1
eq.) were then added, and the yellow solution was stirred at 55C
for 48 hr. The mixture was then concentrated and the residue taken
up with EtOAc, before washing with NaOH 1M (3 times), water,
and brine. The organic fraction was dried over MgSO4 and concen-
trated in vacuo. The residue was puriﬁed by ﬂash chromatography
(dethylene dichloride [DCM]/methanol [MeOH]) to afford the ex-
pected product (1.22 g, 49%). 1H nuclear magnetic resonance
(NMR) (MeOD, 25C) results were as follows: d 0.02–0.05 (m, 27H),
0.98–1.02 (m, 6H), 1.50–1.53 (m, 1H), 2.04–2.08 (m, 1H), 3.19
(t, J = 9.4 Hz, 1H), 3.41–3.75 (m, 14H), 4.11–4.16 (m, 7H), 5.03–
5.10 (m, 4H), 7.29–7.38 (m, 5H); mass spectrometry (MS) (ESI+)
1,074.5 [M+Na]+.
Kanamycin-Teoc3 4
To a solution of Kanamycin-Cbz-Teoc3 (1.3 g, 1.23 mmol, 1 eq.) in
degassed wet MeOH (containing 10% H2O, 50 mL) was added 10%
Pd/C (0.17 g, 0.1 eq.). 3 cycles of vacuum-N2 were applied, followed
by 3 cycles of vacuum-H2. The mixture was stirred overnight, then
ﬁltered over a pad of cellite and washed with EtOH. The ﬁltrate was
concentrated in vacuo and the residue puriﬁed by ﬂash chromatog-
raphy (DCM-MeOH) to afford the expected free amine (0.671 g,
59%). 1H NMR (MeOD, 25C) results were as follows: d 0.00–
0.02 (m, 27H), 0.93–0.95 (m, 6H), 1.46–1.52 (m, 1H), 1.98–2.07
(m, 1H), 2.59–2.64 (m, 1H), 2.92–2.96 (m, 1H), 3.04–3.09
(t, J = 9.3 Hz, 1H), 3.32–3.57 (m, 4H), 3.60–3.69 (m, 9H), 4.03–
4.13 (m, 7H), 5.01 (s, 2H), 5.12 (s, 1H); MS (ESI+) 939.6 [M+Na]+.
(Cholesteryloxy-3-carbonyl)]Kanamycin-Teoc3 5
Et3N (0.12 mL, 1.5 mL, 0.87 mmol, 1.2 eq.) and cholesteryl chlorofor-
mate (0.330 g, 0.73 mmol, 1 eq.) were added to a solution of Kana-
mycin-Teoc3 (0.670 g, 0.73 mmol, 1 eq.) in tetrahydrofuran (THF;
70 mL) and DMF (15 mL). The mixture was stirred at RT overnight,
then concentrated in vacuo. The residue was puriﬁed by ﬂash chro-
matography (DCM-MeOH) to afford the expected product (0.655
g, 67%). 1H NMR (MeOD, 25C) results were as follows: d 0.00–
0.02 (m, 27H), 0.67 (s, 3H), 0.82–1.59 (m, 39H), 1.84–2.02 (m, 6H),
2.27–2.29 (m, 2H), 3.07–3.09 (m, 1H), 3.33–3.39 (m, 6H), 3.53–
3.69 (m, 9H), 3.86–3.89 (m, 1H), 4.02–4.11 (m, 6H), 4.55 (s, 1H),
5.01–5.01 (m, 2H), 5.34 (s, 1H); MS (ESI+) 1,352.0 [M+Na]+.
CholK
To a suspension of (Cholesteryloxy-3-carbonyl)]Kanamycin-Teoc3
(0.650 g, 0.49 mmol) in DCM (6 mL) was slowly added triﬂuoroacetic
acid (TFA; 12 mL) at 0C. The solution was stirred at RT for 2 hr and
then concentrated. After 3 consecutive additions of MeOH and sub-
sequent evaporations, the residue was puriﬁed by ﬂash chromatog-
raphy (reverse phase, C18-Silica, H2O + 0.05% TFA-MeOH) and
lyophilized to give CholK (0.370 g, 61%). 1H NMR (MeOD, 25C)
results were as follows: d 0.72 (s, 3H), 0.87–1.63 (m, 34H), 1.85–64 Molecular Therapy: Nucleic Acids Vol. 14 March 20192.07 (m, 6H), 2.32–2.34 (m, 2H), 2.45–2.55 (m, 1H), 3.17–3.19
(m, 1H), 3.35–3.88 (m, 15H), 4.30–4.50 (m, 1H), 5.10 (s, 1H), 5.26
(s, 1H), 5.38 (s, 1H); MS (ESI+) 919.4 [M+Na]+.
Preparation and Sizing of CholK-mRNA Complexes
CholK was prepared by In-Cell-Art (Nantes, France). To prepare
RNA-CholK nanoparticles, IVT mRNA and CholK were individu-
ally diluted in RiLa to 20 mL and mixed to generate a low charge
ratio (+/) particle (10 mg mRNA and a 1:10 charge ratio [+/]
of CholK:mRNA). The CholK solution was then added to IVT
mRNA, mixed well, and allowed to incubate for 15 min prior to in-
jection. Size and zeta potential of particles were measured with the
Malvern Instruments Zetasizer Nano ZS. Particles were diluted in
PBS to measure size or deionized water to measure zeta potential.
i.m. Injection
Female BALB/c mice (Charles River Laboratories, Wilmington, MA)
were anesthetized with 2.5% isoﬂurane. The region around their ante-
rior tibialis was shaved and then swabbed with isopropanol. 10 mg
(40 mL) IVTmRNA diluted in RiLa was then injected into the anterior
tibialis using a 29G needle. The alternate leg served as a sham injec-
tion control. Mice were housed and manipulated under speciﬁc-path-
ogen-free conditions in the animal care facilities of Georgia Institute
of Technology. All experiments were in accordance with the Institu-
tional Animal Care and Use Committee.
Tissue PLAs
For histological PLAs, samples were initially deparafﬁnized. Antigen
retrieval and permeabilization were performed prior to PLA as
described above. To perform PLA, samples were blocked for 1 hr
with a solution containing 0.5% Tween-20, 0.1% Triton X-100,
0.1% gelatin (Aurion, Wageningen, the Netherlands), 2% donkey
serum (VWR, Radnor, PA), and 1% BSA (EMDBiosciences, St. Louis,
MO) in PBS. Samples were then stained with the indicated antibodies
(anti-TLR7 and anti-IRAK4; anti-RIG-I and anti-MAVS; or anti-
MDA5 and anti-MAVS) overnight at 4C, diluted 1:500 in a solution
of 0.25% gelatin, 0.5% donkey serum, and 1% BSA in PBS. All remain-
ing steps were in accordance with the manufacturer’s instructions
(Sigma-Aldrich, St. Louis, MO).
Tissue PLA Imaging, Quantification, and Statistics
Images were acquired with an UltraVIEW spinning disk confocal mi-
croscope utilizing a Hamamatsu Flash 4.0 v.2 sCMOS camera. A 40,
NA 1.3 Zeiss EC Plan-Neoﬂuar oil objective was used for all tiled im-
ages, and a 63, NA 1.4 Zeiss Plan-Apochromat oil objective was used
for all other images. Imaging was controlled by Volocity acquisition
software (PerkinElmer, Waltham, MA). Image stacks were recorded
at 350-nm intervals. Tiled images were stitched usingVolocity. Six im-
ages were acquired of each tissue section, and a total of four animals
were used per group per time point. The PLA signal-imaging frame
was quantiﬁed using Volocity software. The PLA puncta were identi-
ﬁed as objects with a signal above a minimum threshold. The sum of
PLA signal volume wasmeasured for each frame. Two different statis-
tical methods were used, depending on the number of time points in
www.moleculartherapy.orgthe experiment. For single-time point experiments, a one-way Krus-
kal-Wallis ANOVA test was usedwith aDunn’smultiple comparisons
test. For multiple-time point experiments, a two-way ANOVA was
used with a Tukey’s multiple comparisons test. Statistics were per-
formed in GraphPad Prism 7.0.
In Vitro PLAs on RAWCells Transfected with IVTmRNAwith and
without MTRIP Label
RAW 264.7 macrophage cells were seeded onto 96-well plates. Cells
were transfected with 250 ng/well modiﬁed or unmodiﬁed GFP
IVT mRNA with and without MTRIP labels using Lipofectamine
2000. Cells were processed for PLAs 2 hr later, as described above.
Tissue Immunohistochemistry
Extracted tissue was ﬁxed overnight using 4% paraformaldehyde in
PBS. Tissue was embedded in parafﬁn and sectioned to 5 mm thick.
To stain tissue, sections were deparafﬁnized, antigen retrieval was
performed in citrate buffer (Dako, Carpinteria, CA) for 20 min under
steam, and then tissue was permeabilized in PBS with 0.1% Tween-20
(Calbiochem, Waltham, MA) (PBST) for 10 min. Tissue was blocked
with 5% donkey serum in PBST, incubated with primary antibodies
(at a 1:200 dilution) overnight at 4C in PBST, washed three times
in PBST, incubated with the secondary antibody for 1 hr in PBST,
stained with DAPI, and then mounted with prolong gold (Life Tech-
nologies, Waltham, MA).
Flow Cytometry and Statistics
Lymph nodes and muscle were removed with the assistance of the
Fluobeam NIR imaging system (Fluoptics, Cambridge, MA), at the
indicated time points. Muscle tissue was dissociated with Type IV
collagenase (Worthington Biochemical, Lakewood, NJ) for 1.5 hr at
37C with gentle agitation. Lymph node and muscle samples were
then dissociated by straining through a 40-mm cell strainer with gentle
agitation from a syringe plunger. Cells were washed in PBS + 2% FBS,
blocked with Fc block (BD Biosciences, San Jose, CA) according to the
manufacturer’s directions, and then stained with a panel of antibodies
diluted 1:100 in PBS with Fc block for 30 min on ice. Cells were
washed with PBS + 2% FBS, ﬁxed with 4% paraformaldehyde in
PBS for 10 min, washed with PBS + 2% FBS, and stored at 4C until
analysis. Flow cytometry was performed with a BD LSRII and
analyzed with FlowJo software. Samples were stained using two
different antibody panels, either anti-F4/80 BV421, anti-LYVE1
Alexa 488 (eBioscience, Waltham, MA), I-Ad PE, anti-CD11c
APC-Cy7, and anti-CD11b Alexa 647 or anti-CD3 BV421, anti-
CD45R Alexa 488 (BioLegend, San Diego, CA), anti-CD335 PE,
anti-CD11b Alexa 647, and anti-CD19 APC-Cy7. IVT mRNA was
labeled with DyLight 680. All antibodies were purchased from BD
Biosciences unless otherwise noted. ANOVA followed by Hsu’s mul-
tiple comparison with best post analysis was performed to determine
signiﬁcance using JMP Pro software (SAS, Cary, NC).
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Figure S1: Representative images of controls for PLA of PRR activation kinetics. RAW 264.7 
macrophages were incubated with the following agonists: 8 µg/ml of imiquimod for TLR7, 10 µg/ml of 5’ppp 
dsRNA for RIG-I, 0.1 µg/ml of poly(I:C) for MDA5, 1 µg/ml of LPS for TLR4-TIRAP, and 10 µg/ml of LPS for 
TLR4-TRAM or left untreated. Cells were fixed with 1% paraformaldehyde or methanol as previously indicated 
after 30 minutes or 6 hours. Also at 6 hours, agonists were removed and cells were incubated with media for 3 
additional hours before fixing. PLA was performed between TLR7-IRAK4, RIG-I-MAVS, MDA5-MAVS, TLR4-
TIRAP, and TLR4-TRAM. Representative images of PLA (white) are shown. Extended focus images are 
shown. Scale bar is 10 µm. 
 
 
 
 
  
Figure S2: Representative images of controls for PLA of mRNA PRR activation. RAW 264.7 
macrophages were either untreated, transfected with lipofectamine 2000 (L2K) alone, or transfected with 200 
ng of unmodified or modified IVT GFP mRNA or 200 ng of luciferase IVT mRNA via L2K. Cells were fixed with 
either 1% paraformaldehyde or methanol after 30 minutes, 2 hours, 6 hours, or 24 hours. Representative 
images of PLA (white) are shown. Extended focus images are shown. Scale bar is 10 µm. 
 
  
Figure S3: MTRIPs and CholK formulation. A) Schematic representation of MTRIP assembly (Na indicates 
Neutravidin). B) Schematic representation of mRNA labeling with a representative MTRIP. C) Details of CholK 
formulation. 
  
Figure S4: MTRIP labeling does not alter PRR activation of IVT mRNA. A)  250 ng of modified GFP mRNA 
were delivered to RAW 264.7 macrophages with Lipofectamine 2000. After 16 h, cells were fixed and PLA was 
performed. Statistics were performed with a two-way ANOVA with a Tukey’s multiple comparison test, where 
n=30.  * p < 0.015, ** p < 0.0075, *** p < 0.005 and **** p < 0.0001. 95% confidence intervals are shown in 
black. B) 250 ng of unmodified GFP mRNA were delivered to RAW 264.7 macrophages with Lipofectamine 
2000. After 16 h, cells were fixed and PLA was performed. Statistics were performed with a two-way ANOVA 
with a Tukey’s multiple comparison test, where n=30.  * p < 0.02, ** p < 0.07, *** p < 0.0002 and **** p < 
0.0001. 95% confidence intervals are shown in black. 
 
 
 
 
 
 
 
 
  
Figure S5: Distribution of IVT mRNA following injection and cellular uptake. A) Histological section of 
skeletal muscle tissue 1.5 and 16 hours following IM injection into the anterior tibialis of 10 µg of luciferase IVT 
mRNA formulated with CholK or unformulated. IVT mRNA is shown in red, CD11b staining is green, MHCII is 
white, and nuclei (DAPI) is blue. Scale bar is 100 µm.  B) 16 hours following intramuscular injection, the whole 
anterior tibialis was dissociated into a single cell suspension and flow cytometry was performed to characterize 
the immune cells recruited to the muscle and the fraction containing IVT mRNA. Mean values and the standard 
error of measurement are shown (n=3). *indicates p<0.05, ANOVA followed by Hsu's multiple comparison with 
best.  
  
Figure S6: IVT mRNA uptake by TLR7+, RIG-I+, and MDA5+ cells. Histological sections of skeletal muscle 
tissue 16 hours following intramuscular injection into the anterior tibialis of 10 µg of MTRIP-labeled luciferase 
IVT mRNA (not formulated). In the merged image, the indicated PRR is shown in white, IVT mRNA is shown in 
red, and nuclei (DAPI) in blue. Scale bars are 12 µm.  
 
  
Figure S7: TLR7, RIG-I, and MDA5 detection in sham-injection skeletal muscle tissue. Histological 
sections of skeletal muscle tissue 16 hours following intramuscular injection into the anterior tibialis with RiLa. 
In the merged image, the indicated PRR is shown in white, and nuclei (DAPI) in blue. No signal is visible in the 
channel used for IVT mRNA imaging. Scale bars are 12 µm.   
  
Figure S8: Representative images of PRR PLA following sham i.m. injection. Representative images of 
PRR PLA (white) 16 hours following IM injection into the anterior tibialis with RiLa. Extended focus images are 
shown. Scale bar is 20 µm for full images, 5 µm for crops. White boxes show cropped selection. 
  
Figure S9: Representative images captured with Fluobeam of IVT mRNA following i.m. injection. A) 
Intramuscular injection of IVT mRNA into the anterior tibialis. B) Distribution of IVT mRNA following injection. 
The arrow identifies the popliteal lymph node. Image was acquired 16 hours following injection C) Lymph 
nodes collected 16 hours following IVT mRNA injection (from left to right: popliteal, subiliac, and lumbar aortic). 
  
Figure S10: mRNA presence in lymph nodes 1.5 and 16 hours following injection. A) Histological cross-
section of the entire lumbar aortic lymph node 16 hours following intramuscular injection into the anterior tibialis 
of 10 µg of luciferase IVT mRNA. IVT mRNA is shown in red, and lyve-1 staining is shown in green. IVT mRNA 
associates with lyve-1 staining, indicating presence in lymph node lymphatic vessels. Scale bar is 300 µm. B) 
Shows the blow-up image of the area indicated in (a) with scale bar of 50 µm and C) Shows the blow-up image 
of the area indicated in (b) with a scale bar of 18 µm. For both b) and c), the merged image shows mRNA in 
red, Lyve-1 in green and nuclei (DAPI) in blue. It is evident that mRNA is around lymphatic vessels, but does 
not always associate with lyve-1 positive cells. D) Mice were injected with MTRIP-labeled IVT mRNA 
formulated with CholK. 16 hours following injection, the lumbar aortic lymph node was removed and analyzed 
with flow cytometry. Lymph node cells were phenotyped with the indicated markers and the percent of cells 
containing mRNA for each cell type are shown for CholK/mRNA (n=3).  
 
 
